Key inclusion criteria:  Histologically or cytologically confirmed Stage II, IIIA, or select IIIB (T3N2 only) NSCLC of squamous or non-squamous histology Eligible for R0 resection with curative intent at the time of screening Adequate pulmonary function to be eligible for surgical resection with curative intent Eligible to receive a platinum-based chemotherapy regimen Measurable disease, as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Availability of a representative tumor specimen that is suitable for determination of PD-L1 status Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 Normal life expectancy, excluding lung cancer mortality risk Adequate hematologic and end-organ function Negative human immunodeficiency virus (HIV) test at screening Negative serology for active hepatitis B virus (HBV) and active hepatitis C virus (HCV) at screening  Key Exclusion Criteria:  NSCLC with histology of large cell neuroendocrine carcinoma, sarcomatoid carcinoma, or NSCLC not otherwise specified Small cell lung cancer (SCLC) histology or NSCLC with any component of SCLC Any prior therapy for lung cancer Active or history of autoimmune disease or immune deficiency History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan Active tuberculosis Significant cardiovascular disease NSCLC with an activating EGFR mutation or ALK fusion oncogene Known c-ros oncogene 1 (ROS1) rearrangement History of malignancy other than NSCLC within 5 years prior to screening, with the exception of malignancies with negligible risk of metastasis or death Severe infection within 4 weeks prior to initiation of study treatment or any active infection that, in the opinion of the investigator, could impact patient safety Prior treatment with CD127 agonists or immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, anti-TIGIT, and anti-PD-L1 therapeutic antibodies Treatment with systemic immunostimulatory agents Treatment with systemic immunosuppressive medication Pregnancy or breastfeeding